Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

22 Jan 2014

Five physicians named recipients of 2014 Hastings Center Cunniff-Dixon Physician Awards

Five physicians who have distinguished themselves in advancing the practice of palliative care and modeling exemplary skill and compassion at the bedside have been named recipients of the 2014 Hastings Center Cunniff-Dixon Physician Awards.

22 Jan 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

Joint research program in SMA enters initial stage of clinical development

PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Ipsen decided to launch Somatuline for oncology indications

Ipsen today announced new governance in the United States, following its recently announced decision to launch Somatuline for oncology indications. Marc de Garidel will personally oversee this projected launch.

22 Jan 2014

Genetic counseling delivered over telephone as effective as face-to-face counseling, says study

Genetic counseling delivered over the telephone is as effective as face-to-face counseling, finds the largest randomized study to date comparing the two methods. The multi-center study, led by researchers at Georgetown Lombardi Comprehensive Cancer Center, was reported today in the Journal of Clinical Oncology.

22 Jan 2014

Mesothelioma patients treated with radiation before surgery experience speedier recovery

Results of clinical research that treated mesothelioma with radiation before surgery show the three-year survival rate more than doubled for study participants afflicted with this deadly disease, compared to treating with surgery first.

21 Jan 2014

Mutation in bone cells may cause acute myeloid leukemia: Study

Acute myeloid leukemia is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells.

21 Jan 2014

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.

21 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Par Pharmaceutical Companies, Inc. today announced that it has entered into a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals, a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products.

21 Jan 2014

Illumina inks multi-year supply agreement with LabCorp

Illumina, Inc. today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America Holdings. The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

From Illumina, Inc. 21 Jan 2014

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.

20 Jan 2014

New collaboration aims to push cancer diagnostics to the next level

A collaboration between National Cancer Centre Singapore and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence. This new Centre facilitates the use of circulating tumour cells in clinical diagnostics, in order for new technologies to be applied by healthcare institutions.

19 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence, this study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer.

18 Jan 2014

Research findings could lead to life-saving treatments to fight tumor metastasis

A team of researchers from the Cleveland Clinic and Case Western Reserve School of Medicine have identified critical complex mechanisms involved in the metastasis of deadly "triple negative" breast cancers. These tumors are extremely difficult to treat, frequently return after remission, and are the most aggressive form of breast cancer in women. The discovery of this critical interaction of mechanisms could be used to develop new life saving treatments to kill metastatic tumors in TNBC.

17 Jan 2014

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.

17 Jan 2014

Oncology News and Research

Further Reading

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Five physicians named recipients of 2014 Hastings Center Cunniff-Dixon Physician Awards

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Joint research program in SMA enters initial stage of clinical development

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Ipsen decided to launch Somatuline for oncology indications

Genetic counseling delivered over telephone as effective as face-to-face counseling, says study

Mesothelioma patients treated with radiation before surgery experience speedier recovery

Mutation in bone cells may cause acute myeloid leukemia: Study

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Illumina inks multi-year supply agreement with LabCorp

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

New collaboration aims to push cancer diagnostics to the next level

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

Research findings could lead to life-saving treatments to fight tumor metastasis

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News